Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)-- New long-term data from the RELY-ABLE® study, the long-term extension of the pivotal RE-LY®i trial of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation (AF), were today published online in Circulation,1 the journal of the American Heart Association. Pradaxa® is the only treatment among the new generation of direct oral anticoagulants, which has been evaluated in a large set of AF patients for more than four years.1 The long-term results reinforce the safety profile of Pradaxa®, which was originally established in the landmark RE-LY® trial.1,2,3

Help employers find you! Check out all the jobs and post your resume.

Back to news